<p>Homologous recombination repair (HRR) is a DNA repair pathway that helps maintain genomic stability. About one quarter of patients with metastatic castration-resistant prostate cancer (mCRPC) have alterations in HRR genes. For adult patients in the USA with mCRPC harboring HRR gene alterations, the combination of talazoparib plus enzalutamide is an approved treatment option. The objective of this podcast, featuring two nurse practitioners, is to provide information for oncology nurses and advanced practice providers (APPs) on the use of talazoparib plus enzalutamide and its practical implementation aspects in the clinic. We discuss the importance of testing for HRR gene alterations in mCRPC, appropriate dosing and administration, and our clinical experiences of adverse event monitoring and dose modifications as illustrative examples of the role of oncology nurses and APPs in the treatment of mCRPC with talazoparib plus enzalutamide. Podcast and Infographic are available for this article.</p><p><MediaObject ID="MOESM1"> <VideoObject FileRef="MediaObjects/40487_2025_376_MOESM1_ESM.mp4" VideoID="9KZmLMDqA4ZsFTnQSQUvyp"> <Caption Language="En" xml:lang="en"> <CaptionContent> <p>Podcast Video (MP4 172565 KB)</p> </CaptionContent> </Caption> </VideoObject> </MediaObject></p>